Veridex, Arno Reach Deal to Develop CDx for Anti-Progestins | GenomeWeb

NEW YORK (GenomeWeb News) – Arno Therapeutics today announced an agreement with Johnson & Johnson's Veridex to develop a companion diagnostic for identifying patients who may benefit from anti-progestin cancer therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: comprehensive analysis of somatic mutations in breast cancer, and more.

A number of studies indicate that genes might influence political beliefs, Scientific American Mind reports.

Craig Venter's Human Longevity is deeply phenotyping individuals and capturing their genetic profiles to explore aging.

The San Francisco Business Times examines Verily's latest hires.